within Pharmacolibrary.Drugs.ATC.P;

model P01CD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01CD02</td></tr><td>route:</td><td>rectal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Acetarsol is an organic arsenic compound formerly used as an antiprotozoal and antihelminthic agent, especially in the treatment of infections such as amoebiasis and trichomoniasis. It has also seen historical use for the topical treatment of proctitis and refractory infections. Due to concerns regarding arsenic toxicity and the advent of safer alternatives, acetarsol is generally not approved or used in modern clinical practice.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic (PK) studies of acetarsol in human subjects with reported parameters. No data for sex, age, or disease-specific PK available.</p><h4>References</h4><ol><li><p>Forbes, A, et al., &amp; Gazzard, BG (1989). Safety and efficacy of acetarsol suppositories in unresponsive proctitis. <i>Alimentary pharmacology &amp; therapeutics</i> 3(6) 553–556. DOI:<a href=\"https://doi.org/10.1111/j.1365-2036.1989.tb00247.x\">10.1111/j.1365-2036.1989.tb00247.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2518869/\">https://pubmed.ncbi.nlm.nih.gov/2518869</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01CD02;
